Children's Tumor Foundation harnesses interest in rare disease research...
Neurofibromatosis, a genetic disorder that causes tumors to grow on nerves throughout the body and which affects 1 in 3,000 people - that's over 2.5 million worldwide - has no cure and few workable...
View ArticleNew grants support research on mechanics of tumor cells
At the cellular level, cancer can be viewed as a mechanical engineering challenge. The disease alters the structure and function of cells and tissues, which are meant to perform very specific tasks.
View ArticleResearchers uncover novel molecular clues for tumor aggression in...
Researchers at the Johns Hopkins Kimmel Cancer Center report that their study of tumor samples from people with the rare genetic syndrome neurofibromatosis type 1 (NF1) has uncovered novel molecular...
View ArticleFDA grants acceptance to application for selumetinib as treatment for...
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in...
View ArticleCTF, DELopen jointly offer unique opportunities to neurofibromatosis research...
The Children's Tumor Foundation, an innovative and global neurofibromatosis (NF) research foundation announced today a collaboration with DELopen, a DNA-encoded library technology platform sponsored by...
View ArticleMapping genetic links between diseases using data from electronic health records
Physicians use standard disease classifications based on symptoms or location in the body to help make diagnoses. These classifications, called nosologies, can help doctors understand which diseases...
View ArticleStudy provides new insight into neurofibromin-deficient ER+ breast cancer
An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.
View ArticleFDA approves first-ever treatment for patients with inoperable plexiform...
The U.S. Food and Drug Administration has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one...
View ArticleStudy finds potential new therapeutic targets for childhood brain tumors
People with the genetic condition neurofibromatosis type 1 (NF1) are prone to developing tumors on nervous system tissue.
View ArticleStudy analyzes cancer diagnosis in children with birth defects
Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the...
View ArticleStudy suggests new ways to fight aggressive brain cancer
A mouse model of glioblastoma, an aggressive type of cancer that can occur in the brain, suggests that this recalcitrant cancer originates from a pool of stem cells that can be a significant distance...
View ArticleStudy identifies common characteristics of pediatric vestibular schwannomas
Vestibular schwannomas, more commonly known as acoustic neuromas, are benign brain tumors that develop on the balance (vestibular) and hearing or auditory nerves leading from the inner ear to the brain.
View ArticleMouse orthotopic model was used to determine personalized therapy for relapse...
A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma. Malignant...
View ArticleNanotechnological drug delivery system enhances the effectiveness of melanoma...
Researchers at Tel Aviv University, led by Prof. Ronit Satchi-Fainaro of TAU's Department of Physiology and Pharmacology at the Sackler School of Medicine, have developed an innovative...
View ArticleResearchers identify a compound that inhibits growth of schwannomas
Schwannomas are tumors of the peripheral nervous system, which often occur in the genetic disease neurofibromatosis type 2. The research group of Prof. Dr. Helen Morrison at the Leibniz Institute on...
View ArticleNew drug reduces tumor volume and pain in patients with neurofibromatosis type 1
Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials...
View ArticleSodium fluorescein may improve the safety and outcomes of vestibular...
Removing a vestibular schwannoma -; a slow-growing, benign tumor that develops in the nerves connecting the inner ear to the brain -; is a delicate procedure. Surgeons must differentiate the tumor from...
View ArticleOptic nerve activity may trigger the formation of vision-harming tumors in...
In a study of mice, researchers showed how the act of seeing light may trigger the formation of vision-harming tumors in young children who are born with neurofibromatosis type 1 (NF1) cancer...
View ArticleAntihypertension drug may benefit patients with neurofibromatosis type 2
New research led by investigators at Massachusetts General Hospital and Massachusetts Eye and Ear indicates that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2...
View ArticleResearchers identify a brief window of opportunity to prevent NF1-associated...
Researchers at Children's National Hospital identified a vulnerability in a developmental signaling pathway that can be hijacked to drive pediatric low-grade glioma (pLGG) formation, according to a...
View Article